Nyxoah Announces Commercial Launch of Genio® Breakthrough Therapy in the Middle East

Core Insights - Nyxoah has announced the commercial launch of its Genio® system in the Middle East, with the first successful implantation performed at Saudi German Hospital in Dubai [1][6] - Genio is a neuromodulation device designed to treat Obstructive Sleep Apnea (OSA) for patients who cannot tolerate CPAP therapy, marking a significant advancement in treatment options [1][2] - The launch in the UAE represents a historic milestone as the first neurostimulation therapy for OSA in the region, with strong clinical evidence supporting its effectiveness [1][3] Company Overview - Nyxoah is focused on developing innovative treatment alternatives for OSA through neuromodulation, with Genio being its flagship product [2] - The Genio device is battery-free and is inserted through a single incision under the chin, controlled by a wearable device, showcasing the company's commitment to patient-centric solutions [2] - The company has received CE Mark approval for Genio in Europe and is pursuing FDA approval for commercialization in the U.S. following successful clinical studies [3]